178 related articles for article (PubMed ID: 35047421)
1. A Semi-Quantitative Assay to Measure Glycosaminoglycan Degradation by the Urinary Microbiota.
Nguyen VH; Khan F; Shipman BM; Neugent ML; Hulyalkar NV; Cha NY; Zimmern PE; De Nisco NJ
Front Cell Infect Microbiol; 2021; 11():803409. PubMed ID: 35047421
[TBL] [Abstract][Full Text] [Related]
2. Urinary Glycosaminoglycans Are Associated with Recurrent UTI and Urobiome Ecology in Postmenopausal Women.
Neugent ML; Hulyalkar NV; Kumar A; Xing C; Zimmern PE; Shulaev V; De Nisco NJ
ACS Infect Dis; 2023 Apr; 9(4):1022-1032. PubMed ID: 36942838
[TBL] [Abstract][Full Text] [Related]
3. d-Serine Degradation by Proteus mirabilis Contributes to Fitness during Single-Species and Polymicrobial Catheter-Associated Urinary Tract Infection.
Brauer AL; White AN; Learman BS; Johnson AO; Armbruster CE
mSphere; 2019 Feb; 4(1):. PubMed ID: 30814316
[No Abstract] [Full Text] [Related]
4. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis.
Habibi M; Asadi Karam MR; Shokrgozar MA; Oloomi M; Jafari A; Bouzari S
Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574
[TBL] [Abstract][Full Text] [Related]
5. Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis.
Habibi M; Asadi Karam MR; Bouzari S
APMIS; 2016 Jun; 124(6):444-52. PubMed ID: 26918627
[TBL] [Abstract][Full Text] [Related]
6. In vitro studies on the role of glycosaminoglycans in crystallization intensity during infectious urinary stones formation.
Torzewska A; Różalski A
APMIS; 2014 Jun; 122(6):505-11. PubMed ID: 24164670
[TBL] [Abstract][Full Text] [Related]
7. The Pathogenic Potential of Proteus mirabilis Is Enhanced by Other Uropathogens during Polymicrobial Urinary Tract Infection.
Armbruster CE; Smith SN; Johnson AO; DeOrnellas V; Eaton KA; Yep A; Mody L; Wu W; Mobley HLT
Infect Immun; 2017 Feb; 85(2):. PubMed ID: 27895127
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model.
Habibi M; Asadi Karam MR; Bouzari S
Int Immunopharmacol; 2015 Sep; 28(1):70-8. PubMed ID: 26033493
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice.
Guiton PS; Cusumano CK; Kline KA; Dodson KW; Han Z; Janetka JW; Henderson JP; Caparon MG; Hultgren SJ
Antimicrob Agents Chemother; 2012 Sep; 56(9):4738-45. PubMed ID: 22733070
[TBL] [Abstract][Full Text] [Related]
10. Rapid Growth of Uropathogenic
Forsyth VS; Armbruster CE; Smith SN; Pirani A; Springman AC; Walters MS; Nielubowicz GR; Himpsl SD; Snitkin ES; Mobley HLT
mBio; 2018 Mar; 9(2):. PubMed ID: 29511075
[TBL] [Abstract][Full Text] [Related]
11. Glycosaminoglycans and struvite calculi.
McLean RJ; Nickel JC
World J Urol; 1994; 12(1):49-51. PubMed ID: 8012416
[TBL] [Abstract][Full Text] [Related]
12. Probiotics in human gut microbiota can degrade host glycosaminoglycans.
Kawai K; Kamochi R; Oiki S; Murata K; Hashimoto W
Sci Rep; 2018 Jul; 8(1):10674. PubMed ID: 30006634
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of uropathogenic Escherichia coli metapopulation movement during urinary tract infection.
Walters MS; Lane MC; Vigil PD; Smith SN; Walk ST; Mobley HL
mBio; 2012; 3(1):. PubMed ID: 22318320
[TBL] [Abstract][Full Text] [Related]
14. Urinary Glycosaminoglycans are Associated with Recurrent UTI and Urobiome Ecology in Postmenopausal Women.
Neugent ML; Hulyalkar NV; Kumar A; Xing C; Zimmern PE; Shulaev V; De Nisco NJ
bioRxiv; 2023 Jan; ():. PubMed ID: 36711817
[TBL] [Abstract][Full Text] [Related]
15. The glycobiology of uropathogenic E. coli infection: the sweet and bitter role of sugars in urinary tract immunity.
Lupo F; Ingersoll MA; Pineda MA
Immunology; 2021 Sep; 164(1):3-14. PubMed ID: 33763853
[TBL] [Abstract][Full Text] [Related]
16. The Gene Expression Profile of Uropathogenic Escherichia coli in Women with Uncomplicated Urinary Tract Infections Is Recapitulated in the Mouse Model.
Frick-Cheng AE; Sintsova A; Smith SN; Krauthammer M; Eaton KA; Mobley HLT
mBio; 2020 Aug; 11(4):. PubMed ID: 32788379
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Requirements of Escherichia coli in Intracellular Bacterial Communities during Urinary Tract Infection Pathogenesis.
Conover MS; Hadjifrangiskou M; Palermo JJ; Hibbing ME; Dodson KW; Hultgren SJ
mBio; 2016 Apr; 7(2):e00104-16. PubMed ID: 27073089
[TBL] [Abstract][Full Text] [Related]
18. Immune modulation by group B Streptococcus influences host susceptibility to urinary tract infection by uropathogenic Escherichia coli.
Kline KA; Schwartz DJ; Gilbert NM; Hultgren SJ; Lewis AL
Infect Immun; 2012 Dec; 80(12):4186-94. PubMed ID: 22988014
[TBL] [Abstract][Full Text] [Related]
19. Adaptation of Arginine Synthesis among Uropathogenic Branches of the Escherichia coli Phylogeny Reveals Adjustment to the Urinary Tract Habitat.
Hibbing ME; Dodson KW; Kalas V; Chen SL; Hultgren SJ
mBio; 2020 Sep; 11(5):. PubMed ID: 32994329
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of prevalence, immunogenicity and efficacy of FyuA iron receptor in uropathogenic Escherichia coli isolates as a vaccine target against urinary tract infection.
Habibi M; Asadi Karam MR; Bouzari S
Microb Pathog; 2017 Sep; 110():477-483. PubMed ID: 28754265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
